​

Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TWST Stock Forecast

Twist Bioscience (TWST) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $56.00, with a high of $58.00 and a low of $54.00. This represents a 4.28% increase from the last price of $53.70.

$30 $36 $42 $48 $54 $60 High: $58 Avg: $56 Low: $54 Last Closed Price: $53.7

TWST Stock Rating

Twist Bioscience stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

TWST Price Target Upside V Benchmarks

TypeNameUpside
StockTwist Bioscience4.28%
SectorHealthcare Stocks 23.08%
IndustryDiagnostics & Research Stocks15.00%

Price Target Trends

1M3M12M
# Anlaysts225
Avg Price Target$56.00$56.00$50.20
Last Closing Price$53.70$53.70$53.70
Upside/Downside4.28%4.28%-6.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25362-112
Jan, 25362-112
Dec, 24362-112
Nov, 24352-111
Oct, 243621113
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2025Catherine Ramsey SchulteRobert W. Baird$54.00$52.023.81%0.56%
Feb 03, 2025Luke SergottBarclays$58.00$52.759.95%8.01%
Sep 17, 2024Catherine SchulteRobert W. Baird$46.00$48.18-4.52%-14.34%
Jun 05, 2024Subbu NambiGuggenheim$53.00$46.9812.81%-1.30%
May 03, 2024Catherine Ramsey SchulteRobert W. Baird$40.00$32.0124.96%-25.51%
Jan 17, 2024Matthew SykesGoldman Sachs$45.00$34.8429.16%-16.20%
Feb 05, 2023Luke SergottBarclays$32.00$25.3126.43%-40.41%
Jan 03, 2023Evercore ISI$36.00$24.7345.57%-32.96%
Oct 06, 2022Luke SergottBarclays$45.00$38.5116.85%-16.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025ScotiabankOutperformOutperformhold
Feb 03, 2025BarclaysOverweightOverweighthold
Nov 18, 2024Cowen & Co.BuyBuyhold
Oct 01, 2024Evercore ISIOutperformOutperformhold
Aug 06, 2024ScotiabankOutperformOutperformhold
Jun 28, 2024BarclaysOverweightOverweighthold
Jun 13, 2024Cowen & Co.BuyBuyhold
Jun 04, 2024BarclaysOverweightOverweighthold
Jun 04, 2024GuggenheimBuyinitialise
May 06, 2024ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-3.57$-3.15$-4.04$-3.60$-3.60-----
Avg Forecast$-3.55$-3.14$-4.47$-3.72$-3.72$-2.25$-1.66$-1.08$-0.49$0.04
High Forecast$-3.74$-3.31$-5.36$-3.76$-3.73$-2.35$-1.84$-1.85$-0.49$0.04
Low Forecast$-3.36$-2.98$-3.57$-3.66$-3.70$-2.09$-1.50$-0.64$-0.48$0.04
Surprise %0.56%0.32%-9.62%-3.23%-3.23%-----

Revenue Forecast

$50M $190M $330M $470M $610M $750M Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$90.10M$132.33M$203.56M$245.11M$312.97M-----
Avg Forecast$80.88M$130.95M$179.37M$241.58M$310.91M$373.27M$438.47M$522.91M$605.50M$708.05M
High Forecast$77.69M$125.78M$143.50M$240.00M$310.12M$372.11M$434.79M$521.17M$597.70M$698.93M
Low Forecast$84.27M$136.44M$215.25M$242.01M$311.41M$375.62M$440.20M$524.65M$610.70M$714.14M
Surprise %11.40%1.06%13.49%1.46%0.66%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Sep 20 Sep 21 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 20Sep 21Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-139.93M$-152.10M$-217.86M$-204.62M$-208.73M-----
Avg Forecast$-87.97M$-164.95M$-214.13M$-205.80M$-215.37M$-128.91M$-96.84M$-80.93M$-28.14M$2.32M
High Forecast$-105.56M$-197.93M$-256.96M$-246.96M$-216.24M$-136.39M$-106.70M$-107.50M$-28.45M$2.28M
Low Forecast$-70.37M$-131.96M$-171.31M$-164.64M$-214.51M$-121.43M$-86.98M$-37.20M$-27.67M$2.35M
Surprise %59.07%-7.79%1.74%-0.58%-3.09%-----

TWST Forecast FAQ

Is Twist Bioscience stock a buy?

Twist Bioscience stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Twist Bioscience is a favorable investment for most analysts.

What is Twist Bioscience's price target?

Twist Bioscience's price target, set by 7 Wall Street analysts, averages $56 over the next 12 months. The price target range spans from $54 at the low end to $58 at the high end, suggesting a potential 4.28% change from the previous closing price of $53.7.

How does Twist Bioscience stock forecast compare to its benchmarks?

Twist Bioscience's stock forecast shows a 4.28% upside, underperforming the average forecast for the healthcare stocks sector (23.08%) and underperforming the diagnostics & research stocks industry (15.00%).

What is the breakdown of analyst ratings for Twist Bioscience over the past three months?

  • February 2025: 25.00% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 8.33% Strong Sell.
  • January 2025: 25.00% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 8.33% Strong Sell.
  • December 2024: 25.00% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 8.33% Strong Sell.

What is Twist Bioscience’s EPS forecast?

Twist Bioscience's average annual EPS forecast for its fiscal year ending in September is $-2.25 for 2025, a -37.50% decrease from the reported $-3.6 in 2024. The prediction for 2026 is $-1.66, $-1.08 for 2027, $-0.49 for 2028, and $0.04 for 2029.

What is Twist Bioscience’s revenue forecast?

Twist Bioscience's average annual revenue forecast for its fiscal year ending in September is $373.27M for 2025, a 19.27% increase from the reported $312.97M in 2024. The forecast for 2026 is $438.47M, $522.91M for 2027, $605.5M for 2028, and $708.05M for 2029.

What is Twist Bioscience’s net income forecast?

For its fiscal year ending in September, Twist Bioscience's average annual net income forecast is $-129M for 2025, reflecting a -38.24% decrease from the reported $-209M in 2024. The projection for 2026 is $-96.838M, $-80.934M for 2027, $-28.138M for 2028, and $2.32M for 2029.